The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
The fatty acid amide hydrolase (FAAH) inhibitor PF‐3845 acts in the nervous system to reverse LPS‐induced tactile allodynia in mice
Open accessAbstract
BACKGROUND AND PURPOSE Inflammatory pain presents a problem of clinical relevance and often elicits allodynia, a condition in which non‐noxious stimuli are perceived as painful. One potential target to treat inflammatory pain is the endogenous cannabinoid (endocannabinoid) system, which is comprised of CB 1 and CB 2 cannabinoid receptors and several endogenous ligands, including anandamide (AEA). Blockade of the catabolic enzyme fatty acid amide hydrolase (FAAH) elevates AEA levels and elicits antinociceptive effects, without the psychomimetic side effects associated with Δ 9‐tetrahydrocannabinol (THC). EXPERIMENTAL APPROACH Allodynia was induced by intraplantar injection of LPS. Complementary genetic and pharmacological approaches were used to determine the strategy of blocking FAAH to reverse LPS‐induced allodynia. Endocannabinoid levels were quantified using mass spectroscopy analyses. KEY RESULTS FAAH (−/−) mice or wild‐type mice treated with FAAH inhibitors (URB597, OL‐135 and PF‐3845) displayed an anti‐allodynic phenotype. Furthermore, i.p. PF‐3845 increased AEA levels in the brain and spinal cord. Additionally, intraplantar PF‐3845 produced a partial reduction in allodynia. However, the anti‐allodynic phenotype was absent in mice expressing FAAH exclusively in the nervous system under a neural specific enolase promoter, implicating the involvement of neuronal fatty acid amides (FAAs). The anti‐allodynic effects of FAAH‐compromised mice required activation of both CB 1 and CB 2 receptors, but other potential targets of FAA substrates (i.e. µ‐opioid, TRPV1 and PPARα receptors) had no apparent role. CONCLUSIONS AND IMPLICATIONS AEA is the primary FAAH substrate reducing LPS‐induced tactile allodynia. Blockade of neuronal FAAH reverses allodynia through the activation of both cannabinoid receptors and represents a promising target to treat inflammatory pain. LINKED ARTICLES This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue‐8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx.doi.org/10.1111/bph.2011.163.issue‐7
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Genetic deletion of FAAH also reduces mechanical allodynia induced by low-dose LPS, but this anti-allodynia is absent in mice expressing FAAH only in nervous tissue (Booker et al, 2012) and is mediated by both CB 1 and CB 2 receptors.”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Booker et al, 2012
In the citing paper
“Intraplantar administration of PF-3845 also attenuates LPS-induced allodynia (Booker et al, 2012).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Booker et al, 2012
In the citing paper
“Localized administration of low dose (ie, 2.5 μg) LPS evokes tactile allodynia that is attenuated by FAAH inhibition without inducing paw edema (Booker et al, 2012).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Booker et al, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantitative assessment of tactile allodynia in the rat paw
Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., & Yaksh, T. L. (1994) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(94)90144-9 · Cited by 7,740
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Self-citationGuide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Bačkonja, M. (1998) · JAMA · doi:10.1001/jama.280.21.1831 · Cited by 1,529
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Self-citationThe endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., Chambers, J. K., Randall, A. D., & Davis, J. B. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703050 · Cited by 775
Molecular cloning of a human cannabinoid receptor which is also expressed in testis
Gérard, C. M., Mollereau, C., Vassart, G., & Parmentier, M. (1991) · Biochemical Journal · doi:10.1042/bj2790129 · Cited by 698
Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632
The cannabinoid system and immune modulation
Klein, T., Newton, C. A., Larsen, K. A., Lu, L. D., Perkins, I., Nong, L., & Friedman, H. P. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303101 · Cited by 533
Pharmacological Profile of the Selective FAAH Inhibitor KDS-4103 (URB597)
Piomelli, D., Tarzia, G., Duranti, A., Tontini, A., Mor, M., Compton, T. R., Dasse, O. A., Monaghan, E. P., Parrott, J. A., & Putman, D. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00021.x · Cited by 451
Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain
Ahn, K., Johnson, D. S., Mileni, M., Beidler, D., Long, J. Z., McKinney, M. K., Weerapana, E., Sadagopan, N., Liimatta, M., Smith, S. E., et al. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.02.013 · Cited by 439
Self-citationBehavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs
Martin, B. R., Compton, D. M., Thomas, B. F., Prescott, W. R., Little, P., Razdan, R. K., Johnson, M. R., Melvin, L. S., Mechoulam, R., & Ward Susan, J. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90349-7 · Cited by 410
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism
Clapper, J. R., Moreno-Sanz, G., Russo, R., Guijarro, A., Vacondio, F., Duranti, A., Tontini, A., Sanchini, S., Sciolino, N. R., Spradley, J. M., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2632 · Cited by 346 · cited 3×
“In the light of the recent report by Clapper et al. (2010) showing that a peripherally restricted FAAH inhibitor reduces pain responses, we next evaluated whether i.pl. administration of PF-3845 reverses LPS-induced allodynia.”
BackgroundInfluentialLichtman, A. H., Leung, D., Shelton, C. C., Saghatelian, A., Hardouin, C., Boger, D. L., & Cravatt, B. F. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.069401 · Cited by 332
Self-citationBlockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain
Kinsey, S. G., Long, J. Z., O’Neal, S. T., Abdullah, R. A., Poklis, J. L., Boger, D. L., Cravatt, B. F., & Lichtman, A. H. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.155465 · Cited by 330
Self-citationLichtman, A. H., Shelton, C. C., Advani, T., & Cravatt, B. F. (2004) · Pain · doi:10.1016/j.pain.2004.01.022 · Cited by 301
Self-citationCB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms
Beltramo, M., Bernardini, N., Bertorelli, R., Campanella, M., Nicolussi, E., Fredduzzi, S., & Reggiani, A. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04684.x · Cited by 290
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models
Jayamanne, A., Greenwood, R., Mitchell, V. A., Aslan, S., Piomelli, D., & Vaughan, C. W. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706510 · Cited by 287
Iodo-Resiniferatoxin, a New Potent Vanilloid Receptor Antagonist
Wahl, P., Foged, C., Tullin, S., & Thomsen, C. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.1.9 · Cited by 261
Functional disassociation of the central and peripheral fatty acid amide signaling systems
Cravatt, B. F., Saghatelian, A., Hawkins, E. G., Clement, A. B., Bracey, M. H., & Lichtman, A. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401292101 · Cited by 226
Self-citationTargeting CB2 receptors and the endocannabinoid system for the treatment of pain
Anand, P., Whiteside, G. T., Fowler, C. J., & Hohmann, A. G. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.003 · Cited by 220
Boger, D. L., Miyauchi, H., Du, W., Hardouin, C., Fecik, R. A., Cheng, H. W., Hwang, I., Hedrick, M. P., Leung, D., Acevedo, O., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049614v · Cited by 218
Self-citationCannabinoid receptors undergo axonal flow in sensory nerves
Hohmann, A. G., & Herkenham, M. A. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00220-1 · Cited by 199
Tognetto, M., Amadesi, S., Harrison, S., Créminon, C., Trevisani, M., Carreras, M., Matera, M., Geppetti, P., & Bianchi, A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01104.2001 · Cited by 196
Clement, A. B., Hawkins, E. G., Lichtman, A. H., & Cravatt, B. F. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03916.2003 · Cited by 187
Self-citationRusso, R., LoVerme, J., La Rana, G., Compton, T. R., Parrott, J., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Calignano, A., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119941 · Cited by 182
Holt, S., Comelli, F., Costa, B., & Fowler, C. J. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706348 · Cited by 168
Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms
Chang, L., Luo, L., Palmer, J. A., Sutton, S. W., Wilson, S. J., Barbier, A., Breitenbucher, J. G., Chaplan, S. R., & Webb, M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706773 · Cited by 166
Inhibition of peroxisome-proliferator-activated receptor (PPAR)α by MK886
Kehrer, J. P., Biswal, S. S., La, E., THUILLIER, P., Datta, K., Fischer, S. M., & Heuvel, J. P. V. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3560899 · Cited by 165
Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain
Jhaveri, M. D., Richardson, D., Kendall, D. A., Barrett, D. A., & Chapman, V. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3326-06.2006 · Cited by 159
Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms
Chang, L., Luo, L., Palmer, J. A., Sutton, S., Wilson, S. J., Barbier, A. J., Breitenbucher, J. G., Chaplan, S. R., & Webb, M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706699 · Cited by 155 · cited 14×
“Gabapentin and OL-135 were administered 1 h before testing.”
BackgroundInfluentialKanaan, S. A., Saadé, N. E., Haddad, J. J., Abdelnoor, A. M., Atweh, S., Jabbur, S. J., & Safieh‐Garabedian, B. (1996) · Pain · doi:10.1016/0304-3959(96)03068-0 · Cited by 147
Hsieh, G. C., Pai, M., Chandran, P., Hooker, B. A., Zhu, C. Z., Salyers, A. K., Wensink, E. J., Zhan, C., Carroll, W. A., Dart, M. J., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01046.x · Cited by 139 · cited 3×
“, 1995), previous evidence suggests that it is up-regulated in the dorsal horn in neuropathic pain models (Beltramo et al., 2006; Hsieh et al., 2011), hence changes in CB2 expression during a disease state may be responsible for the strong role of CB2 in modulating LPS-induced allodynia.”
BackgroundJhaveri, M. D., Richardson, D. S., Robinson, I., Garle, M. J., Patel, A., Sun, Y., Sagar, D. R., Bennett, A. J., Alexander, S. P. H., Kendall, D. A., et al. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.04.018 · Cited by 122
Kinsey, S. G., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2010) · The Journal of Pain · doi:10.1016/j.jpain.2010.04.001 · Cited by 118
Self-citationNaidu, P. S., Booker, L., Cravatt, B. F., & Lichtman, A. H. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143487 · Cited by 115
Self-citationCannabinoids and PPARα signalling
Sun, Y., Alexander, S. P. H., Kendall, D. A., & Bennett, A. J. (2006) · Biochemical Society Transactions · doi:10.1042/bst0341095 · Cited by 110
Regulation of Inflammatory Pain by Inhibition of Fatty Acid Amide Hydrolase
Naidu, P. S., Kinsey, S. G., Guo, T. L., Cravatt, B. F., & Lichtman, A. H. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.164806 · Cited by 108
Self-citationInhibition of peroxisome-proliferator-activated receptor (PPAR)α by MK886
Kehrer, J. P., Biswal, S. S., La, E., et al. (2001) · Biochemical Journal · doi:10.1042/bj3560899 · Cited by 104
Suplita, R. L., Farthing, J. N., Gutierrez, T., & Hohmann, A. G. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.07.007 · Cited by 104
Staahl, C., Olesen, A. E., Andresen, T., Arendt‐Nielsen, L., & Drewes, A. M. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03433.x · Cited by 86
The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level
Horváth, G., Kékesi, G., Nagy, E., & Benedek, G. (2007) · Pain · doi:10.1016/j.pain.2007.04.032 · Cited by 74
Roche, M., Diamond, M., Kelly, J. P., & Finn, D. P. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.08.001 · Cited by 65
Desroches, J., Guindon, J., Lambert, C., & Beaulieu, P. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.322 · Cited by 63
Masferrer, J. L., Zweifel, B. S., Hardy, M. M., Anderson, G. D., Dufield, D. R., Cortes-Burgos, L. A., Pufahl, R. A., & Graneto, M. J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166967 · Cited by 48
Research works printed but not linked: 1
- Institute of Laboratory Animal Resources, 1996, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council
Cited by
Sorted by citations
The CB2 receptor and its role as a regulator of inflammation
Turcotte, C., Blanchet, M., Laviolette, M., & Flamand, N. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2300-4 · Cited by 632
Cannabinoids and Pain: New Insights From Old Molecules
Vučković, S., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 440
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301
Self-citationThe cannabinoid system and pain
Woodhams, S. G., Chapman, V., Finn, D. P., Hohmann, A. G., & Neugebauer, V. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.015 · Cited by 285
“Indeed, several distinct classes of FAAH inhibitors reduce nociceptive behaviour following hindpaw administration of LPS, and a detailed investigation of the mechanism implicates both CB1 and CB2, but not TRPV1, PPARa, or m-opioid receptors (Booker et al., 2012).”
Turcotte, C., Chouinard, F., Lefebvre, J. S., & Flamand, N. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ru0115-021r · Cited by 258
Metadata
- Authors
- Booker, L., Kinsey, S. G., Abdullah, R. A., Blankman, J. L., Long, J. Z., Ezzili, C., Boger, D. L., Cravatt, B. F., & Lichtman, A. H.
- Affiliations
- Virginia Commonwealth University (US)
- Scripps Research Institute (US)
- Corresponding author
- Lichtman, Aron H
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-03-23
- Volume
- 165
- Issue
- 8
- Pages
- 2485-2496
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC3423256
- OpenAlex
- W1500005891
- Cited by
- 116
- References
- 49
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 5 · 2023: 2 · 2022: 3 · 2021: 17 · 2020: 4 · 2019: 10 · 2018: 7 · 2017: 13 · 2016: 8 · 2015: 9 · 2014: 11 · 2013: 11 · 2012: 3
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Pharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (R01DA015648, P01DA009789, R01DA015683, F31DA028333, P01DA017259, R01DA003672, R01-DA-03672, P50DA005274, T32DA007027)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Keywords
- fatty acid amide hydrolase, FAAH inhibitors, anandamide, endocannabinoid system, mechanical allodynia, inflammatory pain, lipopolysaccharide, CB1 receptor, CB2 receptor, antinociception, spinal cord, brain, URB597
- MeSH terms
- Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Arachidonic Acids, Brain, Enzyme Inhibitors, Female, Glycerides, Hyperalgesia, Inflammation, Lipopolysaccharides, Male, Mice, Inbred C57BL, Piperidines, Pyridines, Spinal Cord, Peripheral Nervous System, Mice, Knockout, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2, Mice, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
